Vagal Reflex Bradycardia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for vagal reflex bradycardia. 18 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
18
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Vagal Reflex Bradycardia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Yonsei University 18 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating vagal reflex bradycardia. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
26
5
28
1
29
1
30
1
32
1
33
1
35
2
36
5
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Glycopyrrolate Yonsei University 18 53 — 2026-08-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10940110 Glycopyrrolate method of use 75 2029-02-26
11278683 Glycopyrrolate formulation 68 2026-08-16
10744277 Glycopyrrolate method of use 62 2036-12-07
8479730 Glycopyrrolate formulation 55 2028-10-11
8479730 Glycopyrrolate formulation 55 2028-10-11
8182838 Glycopyrrolate formulation 55 2028-10-20
8182838 Glycopyrrolate formulation 55 2028-10-20
9265900 Glycopyrrolate formulation 55 2028-12-07
12151020 Glycopyrrolate formulation 55 2038-10-25
12383491 Glycopyrrolate formulation 55 2038-10-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10688518 Glycopyrrolate formulation 42 2036-11-12
10376661 Glycopyrrolate formulation 42 2035-09-14
9604018 Glycopyrrolate formulation 42 2033-05-16
9168556 Glycopyrrolate formulation 42 2032-09-01
9789270 Glycopyrrolate formulation 48 2030-10-30
10456354 Glycopyrrolate formulation 50 2038-10-25
11110054 Glycopyrrolate formulation 50 2038-10-25
12383491 Glycopyrrolate formulation 55 2038-10-25
11938217 Glycopyrrolate formulation 55 2038-10-25
12151020 Glycopyrrolate formulation 55 2038-10-25

Related